在晚期食道状细胞癌中使用toripalimab和anlotinib的联合治疗:一个病例报告
Si-Cong Chen1, Dong-Heng Ma1, Jia-Jian Zhong2
1Hepatobiliary and Pancreatic Surgery, Huazhong University of Science and Technology Union Shenzhen Hospital, Shenzhen 518052, Guangdong Province, China.
托里帕利马布与安洛丁尼布结合治疗晚期食道状细胞癌 (ESCC) 是有前途的. 这种组合疗法在1名患者中实现了完整的反应,为无法切除的ESCC提供了进一步的临床试验.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 托利帕利马布和安洛丁尼布已被批准用于晚期或不可切除的食道癌.
- 这两种药物都显示出显著的客观反应率和无进展生存率.
研究的目的:
- 评估结合toripalimab和anlotinib在患有晚期食道状细胞癌 (ESCC) 的患者的疗效.
主要方法:
- 一名73岁的男性新诊断出晚期ESCC,接受了toripalimab和anlotinib的联合治疗.
- 随着时间的推移,对治疗反应进行了监测.
主要成果:
- 在3个月的联合治疗后,获得了完整的反应.
- 缓解持续时间长达14个月.
结论:
- 与托利帕利马布和安洛丁尼布的联合治疗为无法切除的ESCC提供了一个有前途的治疗选择.
- 建议进行进一步的临床试验以验证这些发现.
更多相关视频
09:38Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
Published on: June 26, 2019
09:38Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
Published on: August 11, 2017
相关概念视频
Tumor Immunotherapy
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Targeted Cancer Therapies
There are several types of targeted therapies against...
Treatment Resistant Cancers
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
